Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor. Deucravacitinib was approved for medical use in the United States in September 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.<\/p>\n
If deucravacitinib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
SOTYKTU (deucravacitinib) tablets, for oral use Initial U.S. Approval: 2022<\/p>\n
deucravacitinib tablets is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.<\/p>\n
DISEASE INDICATIONS-Psoriasis If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cdeucravacitinib tablets\u201d based on the information you provide.<\/p>\n
\nMANUFACTURER-Bristol-Myers Squibb
\nUSAGE-Oral
\nMEDICINE APPROVED BY-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n